NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABBV stock has increased by 17.3% and is now trading at $99.50. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for AbbVie.

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Friday, May, 1st. The company reported $2.42 EPS for the quarter, beating analysts' consensus estimates of $2.25 by $0.17. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. AbbVie's revenue was up 10.1% compared to the same quarter last year. During the same period last year, the company posted $2.14 EPS. View AbbVie's earnings history.

AbbVie announced a quarterly dividend on Wednesday, June 17th. Investors of record on Wednesday, July 15th will be given a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 annualized dividend and a yield of 4.74%. The ex-dividend date is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie declared that its board has initiated a share repurchase plan on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 brokerages have issued 12-month target prices for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they expect AbbVie's stock price to reach $106.80 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View analysts' price targets for AbbVie.

Press coverage about ABBV stock has trended negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a news impact score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.07%), State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Woodstock Corp (0.01%) and Tsfg LLC (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, HNP Capital LLC, Park National Corp OH, First National Bank of Mount Dora Trust Investment Services, Birch Capital Management LLC, Fulton Bank N. A., M&R Capital Management Inc., and Truehand Inc. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Livforsakringsbolaget Skandia Omsesidigt, Woodstock Corp, Trinity Legacy Partners LLC, Tsfg LLC, Ayalon Holdings Ltd., and Diversified Trust Co. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $99.50.

AbbVie has a market capitalization of $146.94 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.